OBJECTIVE:Inflammation markers can predict restenosis after successful intracoronary stenting. There is evidence that testosterone suppresses the expression of the inflammatory cytokines. We hypothesized that testosterone therapy after coronary stenting can reduce the inflammation markers. METHODS: We selected 41 men with coronary artery disease who underwent successful stent implantation for a >70% diameter stenosis of a major coronary artery. Patients, who had stable angina and positive exercise test results, were recruited after diagnostic coronary angiography. Twenty-five men were treated with 3 doses of i.m. testosterone administration once a week for 3 weeks following diagnostic angiography. Sixteen patients were recruited as a control group and they receivedstandard therapy. First venous blood samples were obtained after angiography. Stents were implanted 3 weeks after diagnostic angiography. Second venous blood samples were taken 24 h after the coronary stenting. RESULTS:Baseline biochemical or hematological parameters were similar between the control and treatment groups. After coronary stenting, free testosterone, total testosterone, and sex hormone binding globulin were significantly elevated in the testosterone group (P<0.0001, P<0.0001 and P=0.02; respectively). After coronary stent implantation, there was a significant increase in IL-6 and CRP levels in the control group only (P=0.02 and P=0.038), while TNF-alpha levels were increased significantly in both groups (P=0.016 and P=0.014; respectively). Statistical analysis revealed that testosterone treatment prior to stent implantation attenuated IL-6 and hs-CRP levels significantly (P=0.042 and P=0.043; respectively). CONCLUSIONS: The present study shows that 3 weeks testosterone treatment prior to intracoronary stenting results in a significant suppression in hs-CRP and IL-6 levels after the stent implantation.
RCT Entities:
OBJECTIVE:Inflammation markers can predict restenosis after successful intracoronary stenting. There is evidence that testosterone suppresses the expression of the inflammatory cytokines. We hypothesized that testosterone therapy after coronary stenting can reduce the inflammation markers. METHODS: We selected 41 men with coronary artery disease who underwent successful stent implantation for a >70% diameter stenosis of a major coronary artery. Patients, who had stable angina and positive exercise test results, were recruited after diagnostic coronary angiography. Twenty-five men were treated with 3 doses of i.m. testosterone administration once a week for 3 weeks following diagnostic angiography. Sixteen patients were recruited as a control group and they received standard therapy. First venous blood samples were obtained after angiography. Stents were implanted 3 weeks after diagnostic angiography. Second venous blood samples were taken 24 h after the coronary stenting. RESULTS: Baseline biochemical or hematological parameters were similar between the control and treatment groups. After coronary stenting, free testosterone, total testosterone, and sex hormone binding globulin were significantly elevated in the testosterone group (P<0.0001, P<0.0001 and P=0.02; respectively). After coronary stent implantation, there was a significant increase in IL-6 and CRP levels in the control group only (P=0.02 and P=0.038), while TNF-alpha levels were increased significantly in both groups (P=0.016 and P=0.014; respectively). Statistical analysis revealed that testosterone treatment prior to stent implantation attenuated IL-6 and hs-CRP levels significantly (P=0.042 and P=0.043; respectively). CONCLUSIONS: The present study shows that 3 weeks testosterone treatment prior to intracoronary stenting results in a significant suppression in hs-CRP and IL-6 levels after the stent implantation.
Authors: Luigi Ferrucci; Marcello Maggio; Gian Paolo Ceda; Cesare Beghi; Giorgio Valenti; Giuseppe De Cicco Journal: J Am Coll Surg Date: 2006-07 Impact factor: 6.113
Authors: Samantha Huo; Anthony R Scialli; Sean McGarvey; Elizabeth Hill; Buğra Tügertimur; Alycia Hogenmiller; Alessandra I Hirsch; Adriane Fugh-Berman Journal: PLoS One Date: 2016-09-21 Impact factor: 3.240
Authors: Marcello Maggio; Peter J Snyder; Francesca De Vita; Gian Paolo Ceda; Yuri Milaneschi; Fulvio Lauretani; Michele Luci; Chiara Cattabiani; Helen Peachey; Giorgio Valenti; Anne R Cappola; Dan L Longo; Luigi Ferrucci Journal: Endocr Pract Date: 2014-11 Impact factor: 3.443
Authors: Farid Saad; Antonio Aversa; Andrea M Isidori; Livia Zafalon; Michael Zitzmann; Louis Gooren Journal: Eur J Endocrinol Date: 2011-07-13 Impact factor: 6.664
Authors: Bledar Daka; Thord Rosen; Per Anders Jansson; Charlotte A Larsson; Lennart Råstam; Ulf Lindblad Journal: BMC Cardiovasc Disord Date: 2013-04-18 Impact factor: 2.298
Authors: Peyman Mesbah Oskui; William J French; Michael J Herring; Guy S Mayeda; Steven Burstein; Robert A Kloner Journal: J Am Heart Assoc Date: 2013-11-15 Impact factor: 5.501